Annexon ANNX Interest And Other Non Operating Income Expense
Interest And Other Non Operating Income Expense at other companies
Other financials
Where this comes from
Reported directly by Annexon in its filing.
Tagged under the XBRL concept annx:InterestAndOtherNonOperatingIncomeExpense.
The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Annexon's interest and other non operating income expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Annexon's interest and other non operating income expense?
- Annexon (ANNX) reported interest and other non operating income expense of $1.91M in Q1 2026.
- How has Annexon's interest and other non operating income expense changed year-over-year?
- Annexon's interest and other non operating income expense decreased by 37.3% year-over-year, from $3.05M to $1.91M.
- What is the long-term trend for Annexon's interest and other non operating income expense?
- Over 4 years (2021 to 2025), Annexon's interest and other non operating income expense has grown at a 123.4% compound annual growth rate (CAGR), from $390K to $9.72M.
- What does interest and other non operating income expense mean?
- This metric represents the net financial impact of activities outside of a company's core clinical and operational business functions, such as interest income from cash holdings or interest expense on debt. It captures non-recurring or peripheral financial gains and losses that do not stem from the primary research and development or commercial operations of the biopharmaceutical entity. Monitoring this helps investors distinguish between the company's core operational burn rate and its broader financial management performance.